News

14. 12. 2019

New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

04. 10. 2019

New TAILORx Data: Clinical Outcomes in Patients with High Recurrence Score® Results

21. 08. 2019

German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score® Test

03. 07. 2019

Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score® Test

30. 04. 2019

Results from the Czech OncotypeDX registry of patients with OncotypeDX Breast Recurrence Score results show up to 78% chemotherapy reduction

05. 03. 2019

Presentation about OncotypeDX Breast Recurrence Score at the 10th PragueOnco - Jubilee Interdisciplinary Oncology Colloquium

07. 09. 2018

German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results

03. 06. 2018

Landmark TAILORx Results Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the majority of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy